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RhabdomyosarcomaYes1 kinase has been implicated as a potential therapeutic target in a number of cancers including mel-
anomas, breast cancers, and rhabdomyosarcomas. Described here is the development of a robust and
miniaturized biochemical assay for Yes1 kinase that was applied in a high throughput screen (HTS) of
kinase-focused small molecule libraries. The HTS provided 144 (17% hit rate) small molecule compounds
with IC50 values in the sub-micromolar range. Three of the most potent Yes1 inhibitors were then exam-
ined in a cell-based assay for inhibition of cell survival in rhabdomyosarcoma cell lines. Homology mod-
els of Yes1 were generated in active and inactive conformations, and docking of inhibitors supports
binding to the active conformation (DFG-in) of Yes1. This is the ﬁrst report of a large high throughput
enzymatic activity screen for identiﬁcation of Yes1 kinase inhibitors, thereby elucidating the polyphar-
macology of a variety of small molecules and clinical candidates.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.The Src family of nonreceptor protein tyrosine kinases contains the downregulation of Yes1 by shRNA found signiﬁcant effects on
nine members including Yes1, c-Src, Fyn, Lyn, and Lyk. These ki-
nases have important roles in a variety of cellular functions, such
as cell proliferation, survival, and differentiation.1 c-Src, the most
well characterized member of this family, has been previously
identiﬁed as a proto-oncogene,2 and a number of antagonists have
been inﬂuential for validating c-Src as a therapeutic target.3,4 Like
c-Src, Yes1 kinase activity has been shown to be upregulated in a
variety of cancers, including colon carcinomas,5 melanoma, head
and neck, renal, lung, and stomach cancers.6,1 In brain-metastatic
melanomas7 and malignant mesothelioma,8 it has been shown that
Yes1, and not other family members, such as c-Src, is functionally
involved in the malignant phenotype. A recent study examiningcell survival and growth for basal-like and Her2-positive breast
cancers.9 In a similar manner, the knock down of Yes1 expression
with shRNA in both embryonal and alveolar rhabdomyosarcoma
cell lines (RD and RH30) was found to signiﬁcantly inhibit cell
growth in vitro, thereby implicating Yes1 as a potential therapeutic
target for this aggressive cancer.10 Despite the potential for Yes1 to
be a target for the above-described cancers, there are very few re-
ports on the identiﬁcation of potent and selective inhibitors of Yes1
kinase.11,12 Antagonists of Yes1 would further elucidate the biology
and help to conﬁrm this kinase as a viable target for therapeutic
intervention in a variety of cancers.
The known inhibitors of Yes1 kinase include dasatinib (1)13 and
saracatinib (2)14 (Fig. 1). Saracatinib, currently in phase II/III clini-
cal trials for the treatment of metastatic breast cancer, is an orally
bioavailable tyrosine kinase inhibitor with nanomolar IC50 values
for c-Src, Yes1, Lck, and Bcr–Abl among other kinases.15 Saracatinib
is an ATP competitive, reversible inhibitor of the Src family of ki-
nases that is known to bind the ATP binding site of Yes1 in the ac-
tive conformation. Preclinical models of saracatinib have shown
only modest anti-proliferative effects with more signiﬁcant effects
on invasion and migration.14,15 Dasatinib, an FDA-approved sub-
nanomolar inhibitor of the Src family of kinases and Bcr–Abl, is
used for the treatment of chronic myelogenous leukemia (CML)16
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Figure 2. Number of high-quality actives sorted by inhibitory activity (IC50) in a
Yes1 kinase HTS biochemical assay.
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Figure 1. Known Yes1 kinase inhibitors, dasatinib and saracatinib.
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dasatinib show signiﬁcant anti-proliferative activity against solid
tumor cell lines.18 Importantly, the differing activity proﬁles of
these two compounds, despite their similar targets, may be a con-
sequence of their off-target inhibitory effects.12,19 Anti-cancer
agents with polypharmacological proﬁles can possess enhanced
in vivo efﬁcacy and fewer resistance mechanisms, and the design
of drugs with multiple targets is proving to be a new paradigm
in drug discovery.19,20 Through the discovery and investigation of
additional inhibitors of Yes1 kinase with either distinct polyphar-
macologies or high Yes1 selectivity, we hope to better understand
the role Yes1 kinase plays in cancer.
In an effort to identify novel, potent and more selective Yes1 ki-
nase inhibitors, we employed a high throughput screening (HTS)
approach utilizing an in vitro biochemical assay. The preparation
of compound libraries for quantitative high throughput screening
(qHTS) has been previously described.21 Three kinase-focused
small molecule libraries were screened for Yes1 kinase inhibition
including the GlaxoSmithKline (GSK) Published Kinase InhibitorFigure 3. Inhibition of Yes1 kinase in a biochemical assay for saracatinib (A,Set (367 compounds) attained from GSK through a public–private
partnership,22,23 a collection of purchased kinase inhibitors with
diverse targets (40 compounds), and an in-house library of com-
pounds with annotated biological target information called the
Mechanism Interrogation PlatE (MIPE) (465 compounds). The com-
bined scope of these libraries include preclinical and clinical candi-
dates and a number of approved drugs, the majority of which had
not been identiﬁed as inhibitors of Yes1 kinase previously in the
literature. The MIPE library alone consists of 73 approved drugs,
168 clinical candidates, and 207 preclinical candidates. Utilizing
focused libraries with clinically advanced small molecules provides
a pharmacological context to the hit compounds derived from a
HTS. Accounting for compound overlap between these three
libraries, a total of 845 small molecules were examined for Yes1
kinase inhibitory activity and 144 (17%) of these were discovered
to be sub-micromolar hits.
Yes1 kinase activity was measured via a ADP-Glo™ Kinase As-
say that quantiﬁes the kinase–dependent enzymatic production
of ADP from ATP using a coupled luminescence-based reaction.24
The kinase activity was evaluated with an 11-point dose curve
(1.3 nM to 76.9 lM) in a 1536-well format for each compound
(PubChem AID 686947). Each plate that was screened had a posi-
tive control (dasatinib), neutral control (DMSO + enzyme), and a
no enzyme control (DMSO only) allowing for comparison of data
between multiple plates. Screening data were corrected and nor-
malized, and concentration-response curves were derived using
in-house algorithms.21 The averaged statistical parameters for
the screen (Z0 = 0.76 ± 0.05, S/B = 23.7 ± 1.95, %CV(DMSO) =
6.9 ± 1.8) provided conﬁdence in the quality of the assay and the
hits. Upon measuring Yes1 kinase IC50 values, the compounds were
sorted based on their efﬁcacy (>50% inhibition) and curve classiﬁ-
cation21,25 (curve classes = 1.1, 1.2, and 2.1) to determine the
percentage of high-quality actives. With these stipulations, the
hit rate for the focused libraries was calculated to be 41% (348/
845). These hits were then sorted by their IC50 values, and 41%
(144/348) exhibited sub-micromolar inhibition, including 53 com-
pounds with IC50s below 100 nM (Fig. 2). The high hit rate for this
screen can be attributed to both the use of kinase-focused libraries
and the relative promiscuity of Yes1.12,26 A previous study proﬁling
72 kinase inhibitors against 442 kinases reported that Yes1 inter-
acts with 26% of the tested inhibitors at 300 nM and up to 45% at
a concentration of 3 lM.12
Compounds that showed greater than 50% inhibition at 1.3 nM
and select additional cherry-picked compounds, were re-examined
in a follow-up assay using a broader 22-point dose curve with a
concentration range of 7.3 fM to 76.9 lM (PubChem AID
686948).27 Notably, all high-quality actives were investigated for
potential reactivity with the assay detection components by run-
ning a counter screen with all of the assay components except
for the Yes1 kinase (PubChem AID 686950).28 There was no ob-
served cross reactivity of the high-quality active small molecules
with the assay components or the coupling enzymes used for theIC50 = 6.2 nM), AMG-Tie-2-1 (B, IC50 = 8.7 nM), AZ-23 (C, IC50 = 39.1 nM).
Table 1
Select Yes1 kinase inhibitors from a HTS and their corresponding clinical phase, known targets, and IC50 values
Compound name
and NCGC ID
Structure Clinical phase Known targets Yes1 IC50 (nM)
Dasatinib (1)
NCGC00181129
S
N
O
NH
NH
N N
N
N OH
Cl
Approved
Lyn, PDGFR, KIT, Lck, BTK, Bcr–Abl,
Fyn, Yes1, c-Src
0.5 (<1.0)a
Saracatinib (2)
NCGC00241099 N
NON
N
O NH O
O
ClO
Phase II/III c-Src, Bcr–Abl, Yes1, Lck 6.2 (0.70)a
AEE-788 (3)
NCGC00263149 N
N NH
NH
N
N
Phase I/II EGFR, HER-2, VEGFR-2 17.5 (13.1)a
Dovitinib (4)
NCGC00249685
HN
O
NH2
F
N
H
N
N
N
Phase III FGFR, EGFR, PDGFR, VEGFR-1,2 31 (1.4)a
DCC-2036 (5)
NCGC00263172
N
N
N
HN
O
HN O
N
O
HNF
Phase I/II Bcr–Abl, Tie-2, Lyn, FLT3, VEGFR-2 2.5 (1.5)a
SGI-1776 (6)
NCGC00263186 N N
N
H
N
N
OCF3
Discontinued Pim-1, FLT3 2670 (240)a
AMG-Tie-2-1 (7)
NCGC00263199
N
O
O
H
N CF3N
NN
H
Preclinical Tie-2 8.7 (22.0)a
AZ-23 (8)
NCGC00250381 N
NCl
N
H
N
H
NHN
O N
F
Preclinical Trk 39.1 (3.0)a
Dorsomorphin (9)
NCGC00165869 N
N
N
O
N N
Preclinical AMPK, BMPR, TGFb Receptor 195.9 (29.8)a
AZ-628 (10)
NCGC00250380
H
N
O
H
N
N
N
ON
Preclinical Raf Kinase B,C 348.3 (51.2)a
a Data in parentheses were gathered by Reaction Biology Corp. using a [c-33P]-ATP radiolabeled enzyme activity assay at an ATP concentration of 10 lM
(www.reactionbiology.com).
4400 P. R. Patel et al. / Bioorg. Med. Chem. Lett. 23 (2013) 4398–4403quantitation of ADP (e.g., luciferase; data not shown) with all
exhibiting curve classes = 4.0, indicating inactive. Figure 3 shows
representative nanomolar inhibition of Yes1 kinase by the small
molecules saracatinib, AMG-Tie-2-1, and AZ-23. The dose–
response curves and Yes1 IC50 values of all tested compounds inthe biochemical assays have been deposited in PubChem and are
available free of charge (http://pubchem.ncbi.nlm.nih.gov/AID
686946).
With a signiﬁcant number of potent inhibitors, we then turned
our attention to examining the reported selectivity and
P. R. Patel et al. / Bioorg. Med. Chem. Lett. 23 (2013) 4398–4403 4401pharmacological properties of a subset of these hits. The high-qual-
ity actives were manually curated to eliminate any compounds
that contained covalent modiﬁers (e.g., Michael acceptors), highly
reactive functional groups, or promiscuous moieties. It is impor-
tant to note that the known Yes1 kinase inhibitors dasatinib (1)
and saracatinib (2) were both components in the screen and were
identiﬁed as potent hits (Fig. 3, and Table 1). Table 1 additionally
shows newly identiﬁed potent Yes1 kinase inhibitors, their current
clinical trial status,29,30 known biological targets29 and Yes1 IC50
values. These compounds were speciﬁcally selected for further
investigation because of the diversity of chemical scaffolds repre-
sented and their relatively advanced pharmacological proﬁles as
a result of their clinical advancement. Although not discussed in
detail, many of the other active hits from these libraries may prove
to be useful tools and amenable to SAR studies for medicinal chem-
istry optimization. To conﬁrm the results of the biochemical assay
described herein, these ten compounds, including dasatinib (1) and
saracatinib (2), were sent to the commercial vendor Reaction Biol-
ogy Corporation for 10-point dose inhibition curves of Yes1 using a
[c-33P]-ATP radiolabeled enzyme activity assay. The IC50 values ob-
tained from Reaction Biology were consistent with the measured
values in our assay. Differences for the values measured by Reac-
tion Biology can be accounted for by the 10-fold lower ATP concen-
trations used in their assay along with general assay variability.
Aside from dasatinib (1) and saracatinib (2), Table 1 shows
three compounds (AEE-788, dovitinib, and DCC-2036, 35) that
have been examined clinically.30 While there is one report of
Yes1 inhibition by dovitinib,26 this is the ﬁrst report of AEE-788
and DCC-2036 demonstrating nanomolar inhibitory activity for
Yes1 kinase. Interestingly, the known primary targets of all of these
compounds include vascular endothelial growth factor receptors
(VEGFR). The compounds AEE-788 (3) and dovitinib (4) are both
angiogenesis inhibitors and are in clinical trials for solid tumors
and glioblastomas among other metastatic cancers.30,31 The com-
pound DCC-2036 (5), on the other hand, is primarily a Bcr–Abl
inhibitor in clinical trials for chronic myeloid and acute lympho-
cytic leukemias.32,33
DCC-2036 (5) also shows nanomolar activity against receptor
tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) and Tie-2 (tyro-
sine kinase with immunoglobulin-like and EGF-like domains),33
both of which are the primary targets for the compounds SGI-
1776 (6)34 and AMG-Tie-2-1 (7),35 respectively. Overexpression
and mutations of FLT3 that lead to constitutive activation and
intracellular signal transduction of this receptor have been impli-
cated in a number cancers, including, chronic and acute myeloid
leukemias.36,37 Similarly, Tie-2 is an endothelial cell speciﬁc recep-
tor tyrosine kinase that upon binding angiopoietin initiates signal
transduction and in this manner plays an important role in
angiogenesis.38 The preclinical candidate AZ-23 (8) is a selective
tropomyosin-related kinase (Trk) inhibitor that exhibits low nano-
molar inhibition in cell-based assays and tumor growth inhibitionFigure 4. Inhibition of cell survival in RD and RH30 rhabdomyosarcoma cell lines for p
IC50[RD] = 10.5 lM, IC50[RH30] = 6.0 lM), and AZ-23 (C, IC50[RD] = 5.3 lM, IC50[RH30] =in a neuroblastoma mouse model.39,40 Trks are activated by soluble
growth factors, including neurotrophins, and thereby induce signal
transduction pathways.41 Interestingly, the altered expression of
Yes1 is thought to play a signiﬁcant role in the progression of mel-
anomas to the brain-metastatic phenotype, and once in the brain,
neurotrophins enhance the activity of Yes1.7 The inhibitory activity
of AZ-23 (8) for both Yes1 and Trk may be responsible for its tumor
growth inhibition in preclinical models. Potent Yes1 kinase inhibi-
tion may play a signiﬁcant role in the biological activity of each of
these compounds.
A few of the most potent Yes1 inhibitors in the biochemical as-
say, were subsequently investigated for cell growth inhibition in
both the RD (embryonal) and RH30 (alveolar) rhabdomyosarcoma
cell lines. Both of these cell lines have recently been shown to dem-
onstrate signiﬁcant growth inhibition in the presence of multiple
Yes1 targeting shRNA sequences.10 Furthermore, this recent study
showed a signiﬁcant growth inhibition of these cell lines in the
presence of the known Yes1 inhibitor dasatinib (1).10 Dasatinib
also exhibited in vivo efﬁcacy in rhabdomyosarcoma xenograft
mouse models of both RD and RH30 tumors.10 The cell-based inhi-
bition curves for the Yes1 inhibitors saracatinib (2), AMG-Tie-2-1
(7), and AZ-23 (8) were measured using a CellTiter-Glo Lumines-
cent Cell Viability Assay at compound concentrations ranging from
0.01–20 lM (Fig. 4).42
Saracatinib (2), one of the most potent Yes1 inhibitors in the
biochemical assay (Fig. 3, and Table 1), showed only moderate
activity for the inhibition of cell growth in the RH30 cell line
(IC50 = 10.1 lM) and did not reach the IC50 in the RD cell line with
the concentrations tested (Fig. 4A). Notably, saracatinib has been
reported to possess signiﬁcant anti-metastatic activity and only
moderate anti-proliferative activity in preclinical models, and our
results in this 48 h cell viability assay support these observations.
AMG-Tie-2-1 (7) and AZ-23 (8) are known potent inhibitors of
Tie-2 and Trk, respectively, both of which are targets that have
yet to be implicated in rhabdomyosarcomas. Nonetheless, AMG-
Tie-2-1 (7) and AZ-23 (8) were found to inhibit cell growth of
the RH30 cell line with IC50 values of 6.0 lM and 1.8 lM, showing
moderate efﬁcacy in the assay (Fig. 4B and C). The RD cell line was
also moderately inhibited by 7 and 8, with IC50 values of 10.5 lM
and 5.3 lM, respectively. The IC50 offset between the biochemical
and cell-based assays for compounds 7 and 8 are consistent with
the previously published data for the known Yes1 kinase inhibitor
dasatinib (1).10,12 Furthermore, the cell activities for 2, 7, and 8 are
expected to be governed by the pharmacological proﬁles of these
compounds and cell permeability and transport. Speciﬁc polyphar-
macology may be necessary for small molecule inhibitors to induce
the anti-proliferative phenotypes for rhabdomyosarcoma cell lines.
Kinase inhibitors with deﬁned polypharmacologies have been suc-
cessful for the treatment of cancers, speciﬁcally solid tumors, with
the advantage of fewer resistance mechanisms.19 Additional stud-
ies would be necessary to delineate these factors.otent Yes1 kinase inhibitors saracatinib (A, IC50[RH30] = 10.1 lM), AMG-Tie-2-1 (B,
1.8 lM).
Figure 5. The interactions of AZ-23 (A) and dovitinib (B) in the ATP-binding pocket
of a Yes1 homology model in an active (DFG-in) conformation with hinge region
hydrogen bonds highlighted.
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inhibitors from our high throughput screen, homology models of
Yes1 were generated. These homology models of Yes1 kinase were
built using publicly available c-Src crystal structures (88% identity
to Yes1) as templates. The high-resolution crystal structures of c-
Src in the active (PDB ID: 1Y57)43 and inactive (PDB ID: 3U4W)44
conformations were selected to construct the active and inactive
conformations of Yes1.45 Because of the high sequence identity
(88%) of Yes1 to c-Src and the availability of high-resolution c-Src
crystal structures, the Yes1 homology models are expected to rea-
sonably reﬂect the binding pocket of Yes1, and are appropriate for
docking small molecules.
The docking of the compounds dovitinib (4) and AZ-23 (8)
among others (not presented here) were examined to both the ac-
tive (DFG-in) and inactive (DFG-out) Yes1 conformations. Both
compounds were unable to bind in the inactive conformation of
the homology model due to signiﬁcant steric interactions with
the Lys38 side chain. Nonetheless, the compounds did bind to
the ATP-binding pocket of the active conformation Yes1 homology
model with little energy minimization required (Fig. 5). The dock-
ing model of AZ-23 (8) to Yes1 was generated by superimposing
the crystal structure of Trk kinase with AZ-23 bound (PDB ID:
4AOJ),46 followed by a series of energy minimizations with the hea-
vy atoms and backbone atoms ﬁxed or tethered. Neither the pro-
tein nor the ligand experienced signiﬁcant changes to reach the
energetically minimized complex structure (Fig. 5A). For the dock-
ing of dovitinib (4), a close analog of this compound in complex
with checkpoint kinase 1 (Chk1) was placed into the ATP binding
site of Yes1 through protein superposition. The ligand was then
transformed into dovitinib by addition of a piperizine group anddeletion of an aminoalkylamino group.47 The energy minimization
was carried out similar to that described above (Fig. 5B). Both com-
pounds show similar binding modes and are within range for
hydrogen bonding with the hinge region amino acids Glu82 and
Met84.
In an effort to identify potent Yes1 kinase inhibitors with en-
hanced selectivity relative to those previously reported, we devel-
oped a biochemical assay amenable to high throughput screening.
This assay was used for the identiﬁcation of potent Yes1 kinase
inhibitors from three kinase-focused libraries including the GSK
Published Kinase Inhibitor Set, a collection of purchased kinase
inhibitors, and an in-house mechanism annotated MIPE library.
From these focused libraries, a signiﬁcant number of potent Yes1
kinase inhibitors were discovered, and this is the ﬁrst report of
the inhibition of this biological target by most of these compounds.
Included among these nanomolar inhibitors, are clinical candidates
such as AEE-788 and dovitinib, along with preclinical candidates,
such as AZ-23 and AMG-Tie-2-1. The small molecules AZ-23 and
AMG-Tie-2-1 showed good activity for the inhibition of cell sur-
vival in two rhabdomyosarcoma cell lines. Finally, the binding
modes of dovitinib and AZ-23 in a Yes1 homology model provided
evidence for binding to the ATP-pocket in the active (DFG-in) con-
formation and key interactions were examined. The results de-
scribed herein provide evidence for the inhibition of Yes1 kinase
as a part of the polypharmacology of a number of known com-
pounds. With the high hit rate from the libraries screened here,
Yes1 inhibition may be an important contributor to the in vivo
activity for a number of kinase inhibitors. The identiﬁcation of even
non-selective inhibitors with diverse polypharmacologies may
help to elucidate the biological role of Yes1 and its role in disease.
Furthermore, the discovery of new potent inhibitors of Yes1 and
examination of their binding modes, may enable the design of
more selective Yes1 kinase inhibitors for use as molecular probes
for this therapeutically relevant biological target.
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